M

Magazine by UseTree
Knowledge, Recommendation Reading Time 2 min | 07.05.2020

COVID-19: AI can help.

The potential of Artificial Intelligence (AI) and Real-World Data (RWD) in medical regulatory, price and reimbursement decision making in the US and Europe

by Redaktion

The current crisis is triggering a fundamental transformation of thinking in many areas of life. Artificial intelligence (AI) and its potential to predict scenarios and conditions with the help of Big Data has always provoked scepticism in politics and business. At present, however, these technologies are becoming increasingly important for supporting decision-making processes during the crisis. But how exactly can this be achieved? In our white paper on “COVID-19: AI can help” we take a deeper look at this topic.

We explore how AI, Big Data and especially Real-World Data (RWD) can be used to support decision-making in the healthcare industry. One of the current topics is decisions on the approval of drugs: What are the concrete challenges and requirements that need to be taken into account?

In our white paper, written in collaboration with Ascenian, we not only explain the terminology, but also give examples where these technologies have already been successfully applied. It shows that AI has the potential to optimise drug approval, pricing and reimbursement decisions. However, this still requires considerable efforts. In this context, we have been able to identify key areas for which all stakeholders involved should develop and pursue a common framework, agreed methods and approaches.

Are you interested in implementing AI in your company to support your business processes?

Get more information in our Executive Summary or the entire White Paper. Here you can download both documents:

You have further questions?

Ascenian and UseTree can support you in the transition process to an AI-based approach. We look forward to hearing from you: info@usetree.de

Bild: Unsplash